Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human

Daniel Chang He; Cheng-Qiang He

doi:10.1186/s12985-022-01945-5

Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human

Virol J. 2022 Dec 8;19(1):209. doi: 10.1186/s12985-022-01945-5.

Authors

Daniel Chang He¹, Cheng-Qiang He^{2

3}

Affiliations

¹ International Department, High School Attached to Shandong Normal University, Jinan, 250014, China.
² Dongying Institute, Shandong Normal University, Dongying, 257000, China. hchqiang@sdnu.edu.cn.
³ Shandong Provincial Key Laboratory of Animal Resistance Biology, College of Life Science, Shandong Normal University, Jinan, 250014, Shandong Province, China. hchqiang@sdnu.edu.cn.

Abstract

For viral diseases, vaccination with live attenuated vaccine (LAV) is one of the most effective means for fighting the diseases. However, LAV occasionally overflows from vaccinated individuals circulate in the population with unforeseen consequences. Currently, SARS-CoV-2 LAVs are undergoing clinical trials. In this study, we found that the viruses isolated from Indian SARS CoV-2 infected persons may be candidate LAV-derived strains, indicating the risk of SARS-CoV-2 LAV spillover from vaccinated persons, increasing the complexity of SARS-CoV-2 detection. In addition, the property of frequent recombination of SARS-CoV-2 increases the chance of LAV virulence reversion. Therefore, how to distinguish the LAV viruses from the wild strain and how to avoid the recombination of the circulating vaccine strain and the wild strain are the challenges currently faced by SARS CoV-2 LAV development.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19* / prevention & control
Humans
SARS-CoV-2 / genetics
Vaccines*

Substances

Vaccines